Share Email Print
cover

Proceedings Paper

Laser immunotherapy for advanced solid tumors
Author(s): Mark Naylor; Xiaosong Li; Tomas Hode; Lu Alleruzzo; Joseph Raker; Siu Kit Lam; Feifan Zhou; Wei Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Immunologically oriented therapy (immunotherapy) has arguably proved to be the most effective method for treating advanced melanoma, the prototypical chemotherapy-resistant solid tumor. The efficacy and benefit of immunotherapy for other tumors, including those that are at least partly responsive to chemotherapy, is less well established. Breast cancer, one of the most common of the solid tumors in humans, is partially responsive to traditional chemotherapy. We believe that breast cancer patients, like melanoma patients, will benefit from the application of immunotherapy techniques. Here we review the different forms of laser immunotherapy (LIT), a key type of immunologically oriented therapy, discuss its use in melanoma and in breast cancer, and discuss its potentially pivotal role in the immunotherapy armamentarium.

Paper Details

Date Published: 7 March 2017
PDF: 4 pages
Proc. SPIE 10065, Biophotonics and Immune Responses XII, 1006509 (7 March 2017); doi: 10.1117/12.2254746
Show Author Affiliations
Mark Naylor, Baylor Scott & White Healthcare (United States)
Xiaosong Li, Univ. of Central Oklahoma (United States)
Chinese PLA General Hospital (China)
Tomas Hode, Immunophotonics, Inc. (United States)
Lu Alleruzzo, Immunophotonics, Inc. (United States)
Joseph Raker, Immunophotonics, Inc. (United States)
Siu Kit Lam, Immunophotonics, Inc. (United States)
Feifan Zhou, Univ. of Central Oklahoma (United States)
Wei Chen, Univ. of Central Oklahoma (United States)


Published in SPIE Proceedings Vol. 10065:
Biophotonics and Immune Responses XII
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top